Plaque psoriasis: SKYRIZI (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Psoriatic arthritis: SKYRIZI alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
If you would like downloadable versions of these videos to share with your patients please contact your AbbVie representative.
- Homecare registration, delivery and injection administration providing care to your patients in their home.
- Support that adapts to the evolving needs of your patients. With AbbVie Care patients benefit from tailored face to face and telephone support* from Homecare nurses. Ensuring the continuation of care from the hospital to their home.
- Following titration one dose per delivery, minimising the risk of waste due to potential treatment changes and reducing the burden on patients by alleviating the need to store multiple doses at their own home.
- Clinical evaluations provided by the SKYRIZI Homecare nurse so that you can feel confident knowing that your patients are supported between hospital visits.
*Telephone support not offered in Scotland.
AbbVie Care is developed and funded by AbbVie Ltd.
For all patients enrolled in the homecare support program provided through AbbVie Care.
I want to find out more about SKYRIZI
I want to receive more information about SKYRIZI
References
- SKYRIZI: Summary of Product Characteristics.
- SKYRIZI Patient Information Leaflet - May 2021.
UK-RISN-220286. Date of preparation: September 2022.
SKYRIZI® (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
SKYRIZI® (risankizumab) alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs.1
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.
SKYRIZI is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.
Some patients may not be suitable for SKYRIZI. You are advised to read the Prescribing Information (which can be found on tab above). Please also refer to the SKYRIZI Summary of Product Characteristics for important information including special warnings/precautions for use and summary of adverse reactions.
Study design information can be found on the Study Design page.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
